You are here

Home » Content

Tekrarlayan Gebelik Kaybı Bulunan Yüksek Riskli Esansiyel Trombositemili Gebede Tedavi

MANAGEMENT OF HIGH RISK ESSENTIAL THROMBOCYTHEMIA IN PREGNANT WITH RECURRENT PREGNANCY LOSS

Journal Name:

  • Selçuk Tıp Dergisi

Publication Year:

  • 2009

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
Essantial Thrombocythemia (ET) is a disease characterized by an increased platelets count, megakaryocyte hyperplasia and increased thrombotic or hemorrhagic events. ET is frequent in women and 15-20% of patients with ET are diagnosed in childbearing age. Pregnancy loss is more in patients with ET than normal population. Early pregnancy loss occurs in 1/3 of patients with ET. We present a women, with ET complicated with portal vein thrombosis who had 3 early and 1 late pregnancy loss with hydroxyurea treatment. She had live birth after treatment with interferonalfa (IFN-α) and low molecular weight heparin (LMWH). Aims of treatment of pregnant women with ET prevent of maternal complications and pregnancy loss due to vasooclusive events. Thus, treatment with IFN-α, aspirin and LMWH are safe and improve pregnancy outcomes.
Bookmark/Search this post with
Abstract (Original Language): 
Esansiyel trombositemia (ET) tormbositoz, megakaryosit hiperplazisi, kanama veya tombozlar ile karaekterize bir hastalıktır. ET kadınlarda daha sık görülmektedir ve yaklaşık %15-20’sini doğurganlık çağındaki hastalar oluşturmaktadır. ET’li kadınlarda gebelik kayıpları normal popülasyona göre daha sık görülmektedir. Yaklaşık 1/3’ü erken gebelik kayıpları şeklindedir. Hidroksiüre tedavisi altında 3 adet erken gebelik kaybı, 1 adet ölü doğum gerçekleştiren, portal ven trombozu bulunan yüksek riskli bir ET hastasında interferon-alfa (IFN-α) ve düşük moleküler ağırlıklı heparin (DMAH) tedavisi ile miadında sağlıklı, canlı doğum gerçekleştiren bir olgu sunulmuştur. ET’li gebelerde tedavi amacı maternal komplikasyonların ve fetal kayıplara neden olacak vazooklüsiv olayların önlenmesi olmalıdır. Sonuç olarak ta IFN-α, aspirin ve DMAH tedavisi gebelerde güvenli olduğu ve gebelik sonuçlarını olumlu etkilediği görülmektedir.
FULL TEXT (PDF): 
PDF icon arastirmax-tekrarlayan-gebelik-kaybi-bulunan-yuksek-riskli-esansiyel-trombositemili-gebede-tedavi.pdf
  • 3
167-170
  • Turkish

REFERENCES

References: 

1. Landgren O, Goldin LR, Kristinsson SY,
Helgadottir EA, Samuelsson J, Björkholm
M. Increased risks of polycythemia
vera, essential thrombocythemia, and
myelofibrosis among 24,577 firstdegree relatives of 11,039 patients with
myeloproliferative neoplasms in Sweden.
Blood 2008; 112: 2199-204.
2. Passamonti F, Randi ML, Rumi E, Pungolino
E, Elena C, Pietra D, et al. Increased risk
of pregnancy complications in patients
with essential thrombocythemia carrying
the JAK2 (617V>F) mutation. Blood
2007;110:485-9.
3. Gangat N, Wolanskyj AP, Schwager S,
Tefferi A. Predictors of pregnancy outcome
in essential thrombocythemia: a single
institution study of 63 pregnancies. Eur J
Haematol 2009; 82: 350-3.
4. Elliott MA, Tefferi A. Thrombocythaemia
and pregnancy. Best Pract Res Clin
Haematol 2003; 16: 227-42.
5. Melillo L, Tieghi A, Candoni A, Radaelli
F, Ciancia R, Specchia G, et al. Outcome
of 122 pregnancies in essential
thrombocythemia patients: A report from
the Italian registry. Am J Hematol 2009;
84: 636-40.
6. Harrison C. Pregnancy and its
management in the Philadelphia negative
myeloproliferative diseases. Br J Haematol
2005; 129: 293-306.
7. Liebelt EL, Balk SJ, Faber W, Fisher
JW, Hughes CL, Lanzkron SM, et al.
NTP-CERHR expert panel report on the
reproductive and developmental toxicity
of hydroxyurea. Birth Defects Res B Dev
Reprod Toxicol 2007; 80: 259-366.
8. Thauvin-Robinet C, Maingueneau C,
Robert E, Elefant E, Guy H, Caillot D,
et al. Exposure to hydroxyurea during
pregnancy: a case series. Leukemia 2001;
15: 1309-11.
9. Ballas SK, McCarthy WF, Guo N, DeCastro
L, Bellevue R, Barton BA, et al. Multicenter
Study of Hydroxyurea in Sickle Cell
Anemia. Exposure to hydroxyurea and
pregnancy outcomes in patients with
sickle cell anemia. J Natl Med Assoc 2009;
101: 1046-51.
10. Italia KY, Jijina FF, S C, Nadkarni AH,
Sawant P, Ghosh K, et al. Exposure to
Hydroxyurea During Pregnancy in Sickle-
{beta} Thalassemia: A Report of 2 Cases.
J Clin Pharmacol 2009 Oct 1. [Epub ahead
of print].
11. Harrison CN, Campbell PJ, Buck G,
Wheatley K, East CL, Bareford D, et al.
United Kingdom Medical Research Council
Primary Thrombocythemia 1 Study.
Hydroxyurea compared with anagrelide
in high-risk essential thrombocythemia. N
Engl J Med 2005; 353: 33-45.
12. Doubek M, Brychtova Y, Doubek R,
Janku P, Mayer J. Anagrelide therapy in
pregnancy: report of a case of essential
thrombocythemia. Ann Hematol 2004; 83:
726-7.
13. Pons JC, Lebon P, Frydman R, Delfraissy
JF. Pharmacokinetics of interferon-alpha
in pregnant women and fetoplacental
passage. Fetal Diagn Ther 1995 JanFeb;10:7-10.
14. Martinelli P, Martinelli V, Agangi A,
Maruotti GM, Paladini D, Ciancia R,
Rotoli B. Interferon alfa treatment for
pregnant women affected by essential
thrombocythemia: case reports and a
review. Am J Obstet Gynecol 2004;191:
2016-20.
15. Brenner B, Hoffman R, Carp H, Dulitsky M,
Younis J. Efficacy and safety of two doses
enoxaparin in women with thrombophilia
and recurrent pregnancy loss: the LIVEENOX study. J Thromb Haemost 2005; 3:
227-9.

Thank you for copying data from http://www.arastirmax.com